Last reviewed · How we verify
Cetapril (ALACEPRIL)
Cetapril (generic name: ALACEPRIL) is a Angiotensin Converting Enzyme Inhibitor Small molecule drug developed by Par Pharm. It is currently FDA-approved (first approved 1981) for Essential hypertension.
At a glance
| Generic name | ALACEPRIL |
|---|---|
| Sponsor | Par Pharm |
| Drug class | Angiotensin Converting Enzyme Inhibitor |
| Target | Angiotensin-converting enzyme |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Essential hypertension
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetapril CI brief — competitive landscape report
- Cetapril updates RSS · CI watch RSS
- Par Pharm portfolio CI
Frequently asked questions about Cetapril
What is Cetapril?
Cetapril (ALACEPRIL) is a Angiotensin Converting Enzyme Inhibitor drug developed by Par Pharm, indicated for Essential hypertension.
What is Cetapril used for?
Cetapril is indicated for Essential hypertension.
Who makes Cetapril?
Cetapril is developed and marketed by Par Pharm (see full Par Pharm pipeline at /company/par-pharm).
What is the generic name of Cetapril?
ALACEPRIL is the generic (nonproprietary) name of Cetapril.
What drug class is Cetapril in?
Cetapril belongs to the Angiotensin Converting Enzyme Inhibitor class. See all Angiotensin Converting Enzyme Inhibitor drugs at /class/angiotensin-converting-enzyme-inhibitor.
When was Cetapril approved?
Cetapril was first approved on 1981.
What development phase is Cetapril in?
Cetapril is FDA-approved (marketed).
What does Cetapril target?
Cetapril targets Angiotensin-converting enzyme and is a Angiotensin Converting Enzyme Inhibitor.
Related
- Drug class: All Angiotensin Converting Enzyme Inhibitor drugs
- Target: All drugs targeting Angiotensin-converting enzyme
- Manufacturer: Par Pharm — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Essential hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing